These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9916650)

  • 1. Allogeneic and autologous bone marrow transplantation in single centre experience.
    Hołowiecki J; Wojnar J; Krawczyk-Kuliś M; Kruzel T; Markiewicz M; Kopera M; Wojciechowska M
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S100-3. PubMed ID: 9916650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of allogeneic bone marrow transplantation for 108 adult patients with acute lymphoblastic leukemia: favorable outcome with BMT at first remission and HLA-matched unrelated donor.
    Chim CS; Lie AK; Liang R; Au WY; Kwong YL
    Bone Marrow Transplant; 2007 Aug; 40(4):339-47. PubMed ID: 17572712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM; Le Beau MM; Anastasi J; Williams SF
    Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immuno- and chemotherapy (PTIC).
    Houtenbos I; Bracho F; Davenport V; Slack R; van de Ven C; Suen Y; Killen R; Shen V; Cairo MS
    Bone Marrow Transplant; 2001 Jan; 27(2):145-53. PubMed ID: 11281383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation.
    Graef T; Vaupel M; Fenk R; Ruf L; Zohren F; Germing U; Haas R; Kobbe G
    Hematol Oncol; 2007 Dec; 25(4):170-7. PubMed ID: 17579887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation.
    Hale GA; Tong X; Benaim E; Cunningham JM; Heslop HE; Horwiz EM; Leung W; Rochester RJ; Shearer PD; Srivastava DK; Woodard JP; Bowman LC
    Bone Marrow Transplant; 2001 Jan; 27(2):155-62. PubMed ID: 11281384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
    de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
    Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients Labar B; Suciu S; Zittoun R; Muus P; Marie JP; Fillet G; Peetermans M; Stryckmans P; Willemze R; Feremans W; Jaksic B; Bourhis JH; Burghouts JP; de Witte T;
    Haematologica; 2004 Jul; 89(7):809-17. PubMed ID: 15257932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
    Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.